Clinical pharmacology of oral gemcitabine in patients with advanced solid tumors

被引：0
|
作者：
Veltkamp, S. A.
Callies, S.
Nol, A.
Visseren-Grul, C. M.
Slapak, C.
Beijnen, J. H.
Schellens, J. H. M.
机构：
[1] Netherlands Canc Inst, Amsterdam, Netherlands
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2006年 / 62卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：735 / 735
页数：1
相关论文
共 50 条
  • [31] Phase I clinical and pharmacologic study of docetaxel and gemcitabine in patients with advanced solid tumors; a novel two week schedule
    Obrocea, M
    Davis, TH
    Lewis, LD
    Maurer, LH
    Pipas, JM
    Smith, EL
    Meyer, LP
    Hammond, S
    Rigas, JR
    ANNALS OF ONCOLOGY, 1998, 9 : 95 - 95
  • [32] Gemcitabine and Docetaxel in patients with advanced solid tumors. A GETICS phase I trial
    Jaremtchuk, AV
    Zabra, JJ
    Ferro, A
    Aman, EF
    Alvarez, R
    Arroyo, G
    Marmissolle, F
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S290 - S290
  • [33] Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors
    Duran, I
    Siu, LL
    Chen, EX
    Oza, AM
    Sturgeon, J
    Chin, SF
    Brown, S
    Pond, GR
    Nottage, M
    ANTI-CANCER DRUGS, 2006, 17 (01) : 81 - 87
  • [34] A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors
    Mavroudis, D
    Pappas, P
    Kouroussis, C
    Kakolyris, S
    Agelaki, S
    Kalbakis, K
    Androulakis, N
    Souglakos, J
    Vardakis, N
    Nikolaidou, M
    Samonis, G
    Marselos, M
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2003, 14 (02) : 304 - 312
  • [35] Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors
    van Groeningen, CJ
    Peters, GJ
    Schornagel, JH
    Gall, H
    Noordhuis, P
    de Vries, MJ
    Turner, SL
    Swart, MS
    Pinedo, HM
    Hanauske, AR
    Giaccone, G
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (14) : 2772 - 2779
  • [36] A phase I study of oral ixabepilone in patients with advanced solid tumors
    Deeken, John F.
    Marshall, John L.
    Pishvaian, Michael J.
    Hwang, Jimmy
    Ahlers, Christoph M.
    Clemens, Pamela L.
    Parker, Susan M.
    Iacono, Lisa
    LoRusso, Patricia M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (05) : 1071 - 1078
  • [37] A phase I study of topotecan and gemcitabine in advanced solid tumors
    Derek S. Serna
    Tanios Bekaii-Saab
    Eric H. Kraut
    Investigational New Drugs, 2011, 29 : 1390 - 1394
  • [38] Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors
    He, Jimmy
    Jackson, Christopher G. C. A.
    Deva, Sanjeev
    Hung, Tak
    Clarke, Katriona
    Segelov, Eva
    Chao, Tsu-Yi
    Dai, Ming-Shen
    Yeh, Hsien-Tang
    Ma, Wen Wee
    Kramer, Douglas
    Chan, Wing-Kai
    Kwan, Rudolf
    Cutler, David
    Zhi, Jay
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (07): : 867 - 879
  • [39] Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors.
    Patnaik, Amita
    Tolcher, Anthony
    Beeram, Muralidhar
    Nemunaitis, John
    Weiss, Glen
    Nichols, Gwen
    Middleton, Steven
    Sarapa, Nenad
    Beryozkina, Anna
    Zhi, Jianguo
    CANCER RESEARCH, 2013, 73 (08)
  • [40] Phase I study of oral rigosertib in patients with advanced solid tumors
    Bowles, Daniel W.
    Diamond, Jennifer Robinson
    Lam, Elaine Tat
    Messersmith, Wells A.
    Weekes, Colin D.
    Leong, Stephen
    Gore, Lia
    Lieu, Christopher Hanyoung
    Freas, Elizabeth
    Ren, Chen
    Wilhelm, Francois
    Eckhardt, S. Gail
    Jimeno, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345